Galvani Bioelectronics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Galvani Bioelectronics
FoundedNovember 2016[1]
Key people
Kristoffer Famm (President)[4]
ParentGlaxoSmithKline (55% equity interest)[3]

Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.


It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[3]

Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.[3] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years[3][6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."[7] Additionally, both companies agreed to contribute their existing intellectual property rights.


  1. ^ a b c "Galvani Bioelectronics Website". Galvani Bioelectronics. Retrieved 24 December 2016.
  2. ^ a b "Galvani Bioelectronics". Verily Life Sciences website. Retrieved 24 December 2016.
  3. ^ a b c d e Temperton, James (1 August 2016). "GSK and Google just created a £540m bioelectronic health firm". Wired. Retrieved 24 December 2016.
  4. ^ "Kristoffer Famm Ph.D. - Galvani Bioelectronics". Galvani Bioelectronics. Retrieved 25 December 2016.
  5. ^ Kollewe, Julia (28 August 2017). "Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline". the Guardian. Retrieved 3 August 2018.
  6. ^ "Bioelectric Medicine Market Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future". 23 January 2019. Retrieved 31 January 2019.
  7. ^ "Galvani Bioelectronics". FierceBiotech. Retrieved 13 July 2020.

External links[edit]